U.S. FDA approves Amgen leukemia drug ahead of schedule

December 3, 2014 6:46 PM

1 0

Dec 3 (Reuters) - U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date.

The drug, blinatumomab, which will be sold under the brand name Blincyto, was approved to treat a form of acute lymphoblastic leukemia (ALL) for which there are currently virtually no treatment options.

Read more

To category page